Redeye updates its estimates and valuation following Vitec releasing its Q1 2025 report.
Ahead of Taaleri's Q1 report due on 29 April, we revise our estimates to match the new reporting str...
We raise '25e-'27e adj. EBITA by 10-1% on higher margins Low renegotiation risk 2025 and growth upsi...
Redeye is happy to see that Insplorion has received an order from a large US space company.
Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) publicerade den 23 april 2025 Bolagets delårsr...
Redeye provides an initial comment on the Q1 2025 report from Serstech.
Volvo delivered a mixed report, with EBIT 12% below Infront consensus.
Redeye provides its initial take on Vitec’s Q1 2025 report, which featured sales that roughly aligne...
Q1 report Tuesday, 29 April at 08:30 CET '25e EBITA up 2% 10-5x EBITA in '25e-'27e, 16-19% FCF yield...
Redeye comments on Thunderful Group ahead of its Q1 results, due on 15 May.
On April 22nd, Genetic Analysis AS (“Genetic Analysis” or the “Company”) announced that the Company ...
Redeye presents its preview for Devyser’s Q1 2025 report, due on April 29.
Q1e: revenues of DKK 320m, EBIT of DKK 11m, 3% margin Minor underlying revisions; major guidance rev...
This friday, between 14.00 - 16.00, NextCell Pharma invites investors, analysts, and media to an inv...
Under de senaste sex månaderna har bolaget genomfört tre exits; Blackbuck, Gringo och Juspay, vilket...
Redeye retains its positive view of Hexatronic despite cutting forecasts and Base Case somewhat on t...
'25e-'27e EBITA down 13-8% Adverse impact from stronger SEK '25e EV/EBITA ~8x, ~50% below peers Wha...
We trim '25e-'27e ARR by 1-3% on continued macro weakness Volume-based revenue growth could pick up ...
FX-driven estimate changes Direct tariff impact likely minor NTM EV/EBIT of just below 7x What to l...
Q1e sales -10% y-o-y as programme shutdown headwind remains FX hedge revaluations to drive strong 43...
